Relentless activity in Washington, D.C., this year has encouraged health care practitioners, especially pharmaceutical companies, to understand and implement the provisions of the Inflation Reduction Act (IRA), which features provisions to reduce out-of-pocket costs for prescriptions. will be busy. Limit Medicare drugs, limit what the government pays for.

On Sept. 7, Avarere Health convened experts for a one-hour rapid-fire webinar, “Connecting Legislative Change Preparedness to Equity and Outcome.” The webinar covered other recent actions impacting drug sponsors and healthcare providers, including the launch of the Enhancing Oncology Model (EOM).

IRA Highlights: Changes in Medicare Negotiations, Inflation Rebates, Part D Redesign

The IRA, signed on August 16th, will run for 14 months.

“Policymaking doesn’t stop now that Congress has taken action,” said Managing Director Matt Kazan. That is for CMS and HHS courts to decide. “

Kazan said CMS and HHS will conduct program guidance. This process moves things quickly and is quicker and harder to influence than the normal rulemaking comment process, but it’s also harder to track.. Employees, it’s how the policy works. He said he could shape it.

Ryan Urgo, managing director of health policy, said the IRA is very specific in some areas but vague in others. Urgo said areas that need clarification include:

• Maximum Fair Price (MFP) enforcement related to our policy of negotiating drug prices with Medicare.
• What will happen to the exchange of information between HHS and drug manufacturers in negotiations?

• How zero-cost sharing of vaccines and insulin caps to patients works. Part D’s “smoothing” policy refers to provisions that allow some beneficiaries to pay equal cost shares throughout the year rather than a large lump sum payment.

Kazan and Urgo also spoke about the negotiation process introduced in the IRA. This would require the company to negotiate drug prices with his HHS for the first time. Kazan said his first one-year negotiations will begin in 13 months. He said any company that has a product to choose from for negotiation should consider a contract and rebate strategy under a Part D plan.

“The law states that if you are a drug of choice, you must be covered by a Part D plan. So thinking about how a Part D plan will address this policy is just as important for manufacturers as thinking about the negotiation process itself,” said Kazan.

Urgo pointed out MFP discounts that are excluded from the Average Manufacturer Price (AMP) calculation but included in Medicaid’s Best Price.

“The legislative text seems to say that MFP discounts are recursive and have a dampening effect. [average sales price] And ASP calculation. That will require a complete rethink of how manufacturers of Part B drugs think about their contracting strategy and engagement with providers,” he said.

Kazan highlighted Congress’ recent decision to remove commercial volumes from those paid in connection with inflation rebates. He said it would change the financial obligations manufacturers have to pay and “change the dynamics of how manufacturers think about future pricing and metering.” As part of that calculation, we compare commercial and Medicare volumes. “

Urgo noted that the inflation adjustment period begins immediately before the application period. “Manufacturers know what their target price needs to be, but they don’t have a lot of time before the applicable period actually begins. As far as we’re concerned, that process will have to be fairly curtailed.”

The redesign of Medicare Part D could begin in earnest in 2025, but by 2024, several changes, such as a 5% cap on beneficiaries and changes to low-income subsidy eligibility, will be implemented. Changes will be considered.

“There are a number of very practical benefits associated with the Part D redesign when it comes to the new out-of-pocket limits and smoothing policies. When it comes to negotiating with plan sponsors, it’s costly for manufacturers,” Urgo said.

He worked with the pricing reimbursement and access team to review the actual evidence that exists for negotiable products and what kinds of new purchase agreements would be required to fully retain the provider. Kazan said business units need to stay informed about activities and decisions from CMS and HHS and stay ahead of decisions.

Preparing for EOM rollout

EOM, the successor to the Oncology Care Model (OCM), is expected to roll out on July 1, 2023. According to Avalere Health consultant Blair Burnett, the model takes a more holistic view of cancer care, but is still within reach. Cost of the care model approach.

One of the major changes in this new model is the reduction in cancer types included. EOM covers only 7 of the 21 cancer types that OCM has done. Cancers covered include breast cancer, lymphoma, small bowel/colorectal cancer, prostate cancer, and chronic leukemia. “Despite the reduction in cancer types included, his seven types associated with EOM will account for about half, or about 48 percent, of OCM episodes,” Burnett said.

Monthly Enhanced Oncology Services (MEOS) payments to support larger-scale care transformation efforts will increase from $160 per month per beneficiary for OCM to $70 per month per beneficiary for EOM withdrawn. However, the clinic receives $100 a month for treating “dual-eligible” patients who receive both Medicare and Medicaid. There are two practice redesign risk models, and electronic patient-reported outcomes will be mandatory in his third year.

Maddi Davidson, a consultant at Avalere Health, said the change in methodology, continued commitment, overall shift to value-based care, and the timing of the model will motivate many participants to switch to EOM. said it was expected. She said that the EOM payment method was overhauled from her OCM so that her pricing would be more accurate, as she would be priced using seven separate cancer regression models, whereas in OCM she would only have one. I explained that it is easier to achieve. Certain diagnostic-related groups were also excluded from the calculations. This may appeal to hospital-based practice.

Burnett said Avarere encourages all life sciences companies and manufacturers involved in these changes to “work with preferred accounts to recommend how practices are needed and methodological adjustments and consider participating.” We encourage you to understand what they are doing and how it supports them.” and how those practices relate to external stakeholders. “

The new EOM addresses equitable cancer care in deployment by working with the Cancer Moonshot Initiative to close the gap and address cancer disparities exacerbated by the COVID-19 pandemic. Two ways EOM hopes to close the gaps in health disparities are by implementing patient-reported outcomes and screening medical resources.

Addressing and reducing healthcare disparities

Businesses are starting to look to address health care disparities and health equity. But the first steps in doing so are often the most difficult to initiate.

Associate principal Brigit Kyei-Baffour said every company should start with data. “There are multiple ways that stakeholders can leverage data to address health equity challenges impacting specific patient communities and use data to develop solutions that drive positive outcomes.” she said.

Ensuring the algorithms that collect data are unbiased and tailoring that data to specific populations of interest is just one way companies can begin their health equity journey. .

Sarah Alwardt, Senior Vice President of Advisory Services, agreed, saying that real-world data is always the starting point for companies and should be taken in context. She also talked about how the patient’s perspective has become important in dealing with these issues. Patients and caregivers can provide their perspective after the data is collected to truly understand what the patient wants and what outcome they want from their treatment.

Combining patient perspectives and data helps companies understand actionable next steps and future strategies identified from these perspectives.